July 29, 2024
Journal of Investigative Dermatology: Interleukin 1 Receptor–Associated Kinase 4 is Overexpressed in Hidradenitis Suppurativa Skin and Correlates with Inflammatory Biomarkers
Alice McDonald, et al.
Hidradenitis Suppurativa (HS)
Read More
May 22, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a House Dust Mite Model of Asthma
American Thoracic Society (ATS) 2024
Read More
May 21, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation In Vivo in a Mouse Model
Digestive Disease Week (DDW) 2024
Read More
March 8, 2024
Potent and Selective Oral STAT6 Degraders Inhibit IL-4 and IL-13 Functions in Human Cells and Block TH2 Inflammation in a Mouse Model of Atopic Dermatitis
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
March 8, 2024
Potent and Selective TYK2 degraders, Devoid of JAK Activity, Potently and Completely Suppress IL12/23 and Type I IFN Signaling Pathways
American Academy of Dermatology (AAD) 2024 Annual Meeting
Read More
November 14, 2023
IRAK4 Degradation vs Inhibition
IRAK4 Program Background
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
November 13, 2023
Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
August 16, 2023
Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases
American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
May 18, 2023
Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis
European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2022
The Phase 1 Healthy Volunteer Clinical Trial of KT-474
5th Annual Targeted Protein Degradation (TPD) Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More